title: Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.
authors.affiliation: Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
authors.forename: N D
authors.initials: ND
authors.lastname: James
authors.affiliation: MRC Clinical Trials Unit at UCL, London, UK.
authors.forename: M R
authors.initials: MR
authors.lastname: Sydes
authors.affiliation: Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
authors.forename: N W
authors.initials: NW
authors.lastname: Clarke
authors.affiliation: MRC Clinical Trials Unit at UCL, London, UK.
authors.forename: A W S
authors.initials: AW
authors.lastname: Ritchie
authors.affiliation: MRC Clinical Trials Unit at UCL, London, UK.
authors.forename: M K B
authors.initials: MK
authors.lastname: Parmar
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009503:Neutropenia; D011471:Prostatic Neoplasms; D043823:Taxoids
chemical_list: D043823:Taxoids; D000077143:Docetaxel